ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2026
A RUNX2 reporter is expressed prior to osteochondral differentiation and models metaphyseal dysplasia with maxillary hypoplasia and brachydactyly.
Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
SOX9 and RUNX2 are lineage defining transcription factors that drive differentiation of chondrocyte and osteoblast lineages respectively from osteochondral progenitors. In limb development, these progenitors are specified first by SOX9 expression required for mesenchymal condensation prior to RUNX2 activation and osteochondral differentiation to chondrocyte and osteoblast lineages. Unlike limb development, the anterior craniofacial skeleton arises from multipotent cranial neural crest cells (cNCCs). To examine the temporal activation of SOX9 and RUNX2 within cNCCs, we utilized a combination of immunofluorescence to detect endogenous proteins and mouse genetic reporters to label SOX9 and RUNX2 expressing cells. We find that RUNX2 is expressed broadly throughout cNCCs of the first branchial arch that will give rise to developing mandibular tissue at a timepoint prior to osteochondral lineage determination. Substantial SOX9 expression is activated subsequently within differentiating chondrocytes. These findings were validated by fluorescent reporters inserted in the 3' untranslated regions (3'UTRs) of Sox9 and Runx2. Although the green fluorescent protein (GFP) reporter-based Runx2 reporter did not delete any 3'UTR sequences, homozygous Runx2GFP/GFP pups develop postnatal deficiencies in intramembranous and endochondral ossification that correlate with enhanced expression of RUNX2 protein in osteoblasts and hypertrophic chondrocytes. We find that this RUNX2 upregulation leads to compaction of growth plates, facilitates the transition of columnar chondrocytes to hypertrophy, and restricts terminal hypertrophic differentiation. Runx2GFP/GFP phenotypes model the human disorder, metaphyseal dysplasia with maxillary hypoplasia and brachydactyly, resulting from RUNX2 enhanced activity due to intragenic duplications. Altogether, this reporter model provides a valuable tool for studying RUNX2 function in early cNCC-derived lineages and highlights the high sensitivity of ossification pathways to RUNX2 dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.